Alpine Immune Sciences Inc
ALPN
ALPN was delisted on the 17th of May, 2024.
88 hedge funds and large institutions have $526M invested in Alpine Immune Sciences Inc in 2023 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 34 increasing their positions, 21 reducing their positions, and 5 closing their positions.
240% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 5
67% more funds holding in top 10
Funds holding in top 10: 3 → 5 (+2)
62% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 21
38% more capital invested
Capital invested by funds: $380M → $526M (+$146M)
16% more funds holding
Funds holding: 76 → 88 (+12)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCMIC
Decheng Capital Management III (Cayman)
Grand Cayman,
Cayman Islands
|
+$82.6M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$23.4M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$16.9M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
+$9.86M |
| 5 |
GTC
Ghost Tree Capital
New York
|
+$3.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OFM
Omega Fund Management
Boston,
Massachusetts
|
-$23.1M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$4.94M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$3.51M |
| 4 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
-$3.27M |
| 5 |
TCM
TCG Crossover Management
Palo Alto,
California
|
-$2.6M |
ALPN Hedge Fund Activity: Q3 2023 in Review
88 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Alpine Immune Sciences Inc (ALPN) for Q3 2023, worth a combined $526M — up 38% from $380M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new ALPN positions and 5 closed out — a net gain of 12 holders — while 34 added to existing stakes and 21 trimmed.
The largest buyer was Decheng Capital Management III (Cayman), opening a new position worth an estimated $82.6M. The largest seller was Omega Fund Management, cutting an estimated $23.1M.
- 88 institutional investors held Alpine Immune Sciences Inc (ALPN) as of Q3 2023, up from 76 in Q2 2023.
- Funds reported $526M of Alpine Immune Sciences Inc stock for Q3 2023, up 38% quarter-over-quarter.
- 17 funds opened new Alpine Immune Sciences Inc positions in Q3 2023 and 5 closed out, a net change of +12 holders.
- The largest Alpine Immune Sciences Inc buyer in Q3 2023 was Decheng Capital Management III (Cayman), an estimated $82.6M added.
- The largest Alpine Immune Sciences Inc seller in Q3 2023 was Omega Fund Management, an estimated $23.1M sold.
Based on aggregated 13F filings for Q3 2023.